Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sina Pishgam Daru Novin (SPDN) is a prominent Iranian biotechnology and pharmaceutical company dedicated to the development, production, and distribution of high-value medicinal products. The company specializes in biosimilars and complex generic drugs, with a core focus on therapeutic areas such as hematology, oncology, and endocrinology. SPDN's portfolio includes critical treatments like Enoxaparin Sodium for thrombosis and recombinant proteins such as Somatropin and Pegfilgrastim. With advanced manufacturing facilities located in the Eshtehard Industrial Zone, the company adheres to international GMP standards to ensure the quality of its biological and chemical products. SPDN plays a vital role in the Iranian healthcare sector by providing affordable access to sophisticated therapies and actively pursues international collaborations for technology transfer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Sina Pishgam Daru Novin.